Production (Stage)
Beam Therapeutics Inc.
BEAM
$17.03
$0.201.19%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -187.48% | -184.28% | 54.22% | 56.29% | 57.41% |
| Total Depreciation and Amortization | 5.90% | 9.56% | 17.48% | 27.70% | 34.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.32% | 47.66% | 189.63% | 70.31% | 42.09% |
| Change in Net Operating Assets | 10.81% | 5.35% | -26.95% | -33.71% | -70.37% |
| Cash from Operations | -152.56% | -132.75% | 61.58% | 59.35% | 54.50% |
| Capital Expenditure | 68.25% | 73.48% | 75.09% | 62.28% | 36.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 432.78% | 83.72% | 32.49% | 33.20% | -84.53% |
| Cash from Investing | 1,702.57% | 157.53% | 79.89% | 99.06% | -106.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 83.13% | 78.46% | 49.46% | 44.91% | 21.87% |
| Issuance of Common Stock | 161.03% | -97.06% | -85.91% | -68.95% | 16.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -17.79% | -133.20% |
| Cash from Financing | 164.31% | -97.20% | -86.17% | -69.31% | 17.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 591.73% | -177.60% | 597.01% | 254.94% | 169.46% |